From: Nociceptors in cardiovascular functions: complex interplay as a result of cyclooxygenase inhibition
AA Metabolite | Receptor subtypes | Secondary messenger mechanisms | Tissue distribution of the receptors | Cardiovascular functions of AA metabolites | Ref. |
---|---|---|---|---|---|
PGD2 | DP1, DP2 (CRTH2) | Gs (DP1, 2), Gi, Gq, MAPK (DP2) | Leptomeninges, Langerhan cells, Goblet and columnar cells in GI tract, Eosinophils for DP1, All tissues for DP2 | Vasodilation, Vasoconstriction, Platelet deaggregation | 1, 12 |
PGE2 | EP1, EP3, EP3, EP4 | Gs, Gi, Gq | Kidney, Lung and Stomach for EP1, EP2 expressed in response to LPS and gonadotrophins, EP3 and 4 in all tissues | Vasodilation, Vasoconstriction, Maintain renal blood flow and GFR, Vascular smooth muscle mitogenesis | 1, 12, 15 |
PGI2 | IP | Gs (predominant), Gi, Gq | Neurons, (primarily DRGs), Endothelial cells, Vascular smooth muscle cells, Kidney, Thymus, Spleen and Megakaryocytes | Vasodilation, Inhibit platelet aggregation, Inhibit TXA2-induced vascular proliferation | 1, 12, 21, 58 |
PGF2α | FP | Gq, EGFR | Corpus luteum, Kidney, Heart, Lung and Stomach | Vasoconstriction, Mitogenesis in heart, Inflammatory tachycardia, Renal functions | 1, 12 |
TXA2 | TP | Gq, Gs, Gi, Gh, G12 | Kidney, Heart, Lungs, Platelets and Immune cells | Platelet aggregation, Vasoconstriction, Inflammatory tachycardia | 1, 12, 58 |
20-HETE | ? | Gq, Tyrosine kinase, Increased conductance of L-type Ca2+ channels, Inhibition of Na+-K+-2Cl cotransporter | ? | Renal and cerebral artery contraction, Antagonize EDHF mediated vasorelaxation, Myogenic constriction, Regulate renal functions | 1, 54 |
Leukotrienes (LTB4-E4) | BLT1, BLT2 (LTB4), CysLT1, CysLT2 (LTC4-D4) | ?Gi/Go (BLT1,2, CysLT1,2), Gα16 (BLT1,2) | Leukocytes, spleen, thymus, bone marrow, lymph nodes, heart, skeletal muscle, brain and liver for BLT1, Most tissues for BLT2, | Coronary smooth muscle contraction, Transient pulmonary and systemic hypertension | 1, 54 |
EETs | ? | Gs, Tyrosine kinases, ERK1/2, p38 MAPK, Activation of Ca2+-activated K+ channels | ? | Renal and cerebral vasodilation, Renal vasoconstriction, Vascular smooth muscle and endothelial cell proliferation | 1 |